Table 8 Cumulative survival for Nomo stages in derivation and external validation cohorts
From: Nomograms to predict survival after colorectal cancer resection without preoperative therapy
| Â | Training cohort | Validation cohort | Test cohort | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | (Cumulative survival, 60Â months, %) | (Cumulative survival, 60Â months, %) | (Cumulative survival, 59Â months, %) | |||||||||
Nomo stage | CSS | 95Â % CI | OS | 95Â % CI | CSS | 95Â % CI | OS | 95Â % CI | CSS | 95Â % CI | OS | 95Â % CI |
Nomo 1 | 96.8 | 96.1–97.4 | 94.6 | 93.7–95.4 | 97.7 | 96.1–99.4 | 95.5 | 93.2–97.8 | 94.3 | 88.7–99.8 | 90.8 | 85.5–96.1 |
Nomo 2 | 94.0 | 93.1–95.0 | 88.1 | 86.9–89.3 | 92.9 | 90.0–95.8 | 87.1 | 83.4–90.9 | 94.0 | 91.5–96.6 | 89.0 | 86.5–91.4 |
Nomo 3 | 90.9 | 89.8–92.0 | 83.7 | 82.4–85.1 | 91.2 | 88.0–94.4 | 86.6 | 82.8–90.3 | 92.1 | 90.5–93.6 | 85.5 | 83.4–87.7 |
Nomo 4 | 87.1 | 85.8–88.4 | 76.1 | 74.5–77.7 | 88.1 | 84.4–91.7 | 78.9 | 74.4–83.4 | 87.4 | 84.5–90.3 | 76.5 | 73.5–79.5 |
Nomo 5 | 82.0 | 80.4–83.5 | 70.3 | 68.6–72.0 | 82.3 | 77.9–86.7 | 67.8 | 62.6–73.0 | 83.7 | 81.8–85.7 | 69.1 | 62.1–76.1 |
Nomo 6 | 74.2 | 72.4–75.9 | 59.0 | 57.2–60.9 | 73.6 | 68.5–78.7 | 59.4 | 54.0–64.8 | 76.1 | 73.9–78.4 | 60.1 | 56.9–63.3 |
Nomo 7 | 63.3 | 61.4–65.2 | 44.8 | 42.9–46.7 | 61.3 | 55.6–67.0 | 50.6 | 45.1–56.1 | 64.4 | 60.3–68.6 | 47.4 | 43.3–51.5 |
Nomo 8 | 43.6 | 41.6–45.6 | 32.6 | 30.9–34.4 | 50.8 | 44.8–56.8 | 32.7 | 27.5–37.9 | 49.9 | 46.9–53.0 | 31.8 | 27.9–35.7 |
Nomo 9 | 22.1 | 20.4–23.7 | 18.0 | 16.5–19.4 | 23.9 | 18.8–29.0 | 20.2 | 15.8–24.7 | 20.2 | 16.0–24.4 | 17.8 | 15.0–20.6 |
Nomo 10 | 5.7 | 4.7–6.6 | 4.8 | 4.0–5.6 | 8.4 | 5.2–11.6 | 7.3 | 4.5–10.2 | 6.3 | 3.9–8.6 | 3.8 | 1.3–6.3 |
Plog-rank for trend | <0.0001 | Â | <0.0001 | Â | <0.0001 | Â | <0.0001 | Â | <0.0001 | Â | <0.0001 | Â |